There is limited data availability on effect of Metformin XR on 24-h plasma glucose, and there is no available data in chronic kidney disease (CKD). The planned study aims to provide data on glucose plasma level in relation to metformin plasma level in Diabetes Type II patients.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
12
Metformin extended release tablets (Glucophage 500 mg; 750 mg; 1,000 mg) administrated during 6 to 12 weeks (CKD1 and 3B, respectively)
CHU Amiens Picardie
Amiens, France
Efficacy of once daily Metformin XR on 24-h blood glucose control
The blood glucose will be measured continuously throughout the study using continuous glucose monitoring (mean, range and variability in each therapeutic block).
Time frame: week 12
Tolerability of Metformin XR in mild to moderate (CKD)
Blood creatinine levels will be measured at the end of each therapeutic block. (week 0, 2, 4, 6, 8, 10 and 12)
Time frame: week 0, 2, 4, 6, 8, 10 and 12
Tolerability of Metformin XR in mild to moderate (CKD) 2
blood lactate levels will be measured at the end of each therapeutic block.
Time frame: week 0, 2, 4, 6, 8, 10 and 12
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.